Hengeler Mueller advises Epigenomics AG on takeover offer by Summit Hero Holding

27. April 2017

Epigenomics AG, Cathay Fortune International Company Limited ("CFIC") and Blitz F16-83 GmbH (in the future Summit Hero Holding GmbH, "Bidder"), a subsidiary of CFIC, have entered into a business combination agreement ("BCA") regarding the takeover of Epigenomics by the Bidder. Other than by CFIC, the Bidder will also be indirectly owned by the largest current shareholder of Epigenomics, Biochain, the strategic partner of Epigenomics and a subsidiary of Team Curis Group. Under the terms of the BCA, Epigenomics shareholders will be offered EUR 7.52 in cash per each ordinary share. The transaction values Epigenomics' equity, including net cash, at approximately EUR 171 m and reflects a 49.4% premium to the 3-month volume weighted average share price.  

Epigenomics is a molecular diagnostics company focused on blood-based detection of cancers using its proprietary DNA methylation biomarker technology. The company develops and commercializes diagnostic products across multiple cancer indications with high medical need.  

Hengeler Mueller is advising Epigenomics on the takeover. The Hengeler Mueller team includes partners Kai-Steffen Scholz (Berlin) and Changfeng Tu (Shanghai) as well as associates Steven Leunert, Marlen Thaten (all Berlin) and Tianyuan Zhuang (Shanghai) (all Corporate/M&A).